We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Read MoreHide Full Article
Key Takeaways
TNGX rallied on encouraging vopimetostat data but remains a clinical-stage company without product revenue.
TNGX plans late-stage development for a lead combination and expects multiple 2026 clinical readouts.
TNGX has cash projected into 2028, but future performance still hinges on clinical and regulatory progress.
Tango Therapeutics (TNGX - Free Report) has become one of 2026’s more dramatic biotechnology stories, with shares up 224.3% year to date and 404.1% over the past year.
That rally reflects real clinical progress, but it also raises the bar. Tango remains a clinical-stage company with no approved products, no recurring product revenues and a valuation that already discounts meaningful success.
Why TNGX Bulls See More Upside
The bullish case starts with vopimetostat, Tango’s selective PRMT5 inhibitor for MTAP-deleted cancers. Its MTA-cooperative mechanism is designed to target MTAP-deleted cancer cells while sparing normal tissue, a distinction that could support broader use across pancreatic cancer, lung cancer and other solid tumors.
The strongest near-term excitement comes from the vopimetostat-daraxonrasib combination in previously treated MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. Among 12 evaluable patients, the regimen produced a 92% objective response rate, 100% disease control rate and 90% six-month progression-free survival rate.
That data supports Tango’s plan to move the combination toward late-stage development in first-line MTAP-deleted pancreatic cancer, subject to regulatory feedback. Revolution Medicines (RVMD - Free Report) , Tango’s RAS inhibitor partner, is a relevant comparator because daraxonrasib is its investigational RAS(ON) multi-selective inhibitor for RAS-addicted cancers.
Tango also expects multiple 2026 readouts, including vopimetostat monotherapy data in lung cancer and initial TNG456 data in glioblastoma. Erasca (ERAS - Free Report) adds another combination angle through ERAS-0015, its pan-RAS molecular glue, which Tango plans to evaluate with vopimetostat.
Why Tango Still Carries Real Risk
The bear case is straightforward. Tango has no marketed therapies and has not generated recurring product revenue. Its valuation depends on clinical execution, regulatory progress and eventual commercialization rather than operating cash flow.
The end of recognized Gilead collaboration revenue sharpens that risk. Collaboration revenue was zero in the first quarter of 2026, compared with $5.4 million in the year-ago period, after remaining deferred revenue tied to the Gilead collaboration was recognized in 2025.
That leaves more of the investment case tied to wholly owned programs. Pipeline setbacks, slower enrollment or disappointing later-stage results could weigh heavily because Tango’s clinical focus is still concentrated around vopimetostat and TNG456.
The share-price move has made valuation harder to ignore. Tango’s trailing 12-month book value multiple stands at 10.59X, above 3.64X for its Zacks sub-industry, 4.04X for the broader Zacks sector and 8.10X for the S&P 500.
That premium does not mean the rally is finished. It does mean investors may need stronger clinical evidence before assuming the recent momentum can continue unchecked.
The valuation setup favors selectivity. For new buyers, the stock’s next leg likely depends less on enthusiasm and more on whether upcoming data confirm that vopimetostat can support a larger commercial opportunity.
Why Tango Cash Buys Time but Not Certainty
Tango ended March 31, 2026, with $379.8 million in cash, cash equivalents and marketable securities. Management expects that balance to fund operations into 2028.
That runway matters. It gives Tango time to advance several programs, absorb near-term development spending and pursue key readouts without immediate financing pressure.
Still, cash does not remove clinical risk. Larger late-stage studies could raise spending needs, especially if timelines extend or data force Tango to adjust its development strategy.
How TNGX Ranking Signals Shape the Debate
The bottom line is that TNGX still offers meaningful clinical upside, but the easy part of the trade may have passed. The stock’s premium valuation, lack of product revenue and dependence on upcoming data make the risk-reward profile more balanced after the rally.
TNGX currently carries a Zacks Rank #3 (Hold), along with a Value Score of F, Growth Score of F, Momentum Score of B and VGM Score of F. The Rank points to a neutral near-term earnings estimate backdrop, while the Style Scores suggest strong price momentum but weak value and growth characteristics. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
For investors, those signals are best used as entry-point tools rather than final verdicts. In Tango’s case, the stock remains event-driven, and upcoming clinical updates are likely to matter more than any single ranking metric.
View the Zacks #1 Rank List
Image: Bigstock
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Key Takeaways
Tango Therapeutics (TNGX - Free Report) has become one of 2026’s more dramatic biotechnology stories, with shares up 224.3% year to date and 404.1% over the past year.
That rally reflects real clinical progress, but it also raises the bar. Tango remains a clinical-stage company with no approved products, no recurring product revenues and a valuation that already discounts meaningful success.
Why TNGX Bulls See More Upside
The bullish case starts with vopimetostat, Tango’s selective PRMT5 inhibitor for MTAP-deleted cancers. Its MTA-cooperative mechanism is designed to target MTAP-deleted cancer cells while sparing normal tissue, a distinction that could support broader use across pancreatic cancer, lung cancer and other solid tumors.
The strongest near-term excitement comes from the vopimetostat-daraxonrasib combination in previously treated MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. Among 12 evaluable patients, the regimen produced a 92% objective response rate, 100% disease control rate and 90% six-month progression-free survival rate.
That data supports Tango’s plan to move the combination toward late-stage development in first-line MTAP-deleted pancreatic cancer, subject to regulatory feedback. Revolution Medicines (RVMD - Free Report) , Tango’s RAS inhibitor partner, is a relevant comparator because daraxonrasib is its investigational RAS(ON) multi-selective inhibitor for RAS-addicted cancers.
Tango also expects multiple 2026 readouts, including vopimetostat monotherapy data in lung cancer and initial TNG456 data in glioblastoma. Erasca (ERAS - Free Report) adds another combination angle through ERAS-0015, its pan-RAS molecular glue, which Tango plans to evaluate with vopimetostat.
Why Tango Still Carries Real Risk
The bear case is straightforward. Tango has no marketed therapies and has not generated recurring product revenue. Its valuation depends on clinical execution, regulatory progress and eventual commercialization rather than operating cash flow.
The end of recognized Gilead collaboration revenue sharpens that risk. Collaboration revenue was zero in the first quarter of 2026, compared with $5.4 million in the year-ago period, after remaining deferred revenue tied to the Gilead collaboration was recognized in 2025.
That leaves more of the investment case tied to wholly owned programs. Pipeline setbacks, slower enrollment or disappointing later-stage results could weigh heavily because Tango’s clinical focus is still concentrated around vopimetostat and TNG456.
Tango Therapeutics, Inc. Price and Consensus
Tango Therapeutics, Inc. price-consensus-chart | Tango Therapeutics, Inc. Quote
How TNGX Valuation Complicates the Call
The share-price move has made valuation harder to ignore. Tango’s trailing 12-month book value multiple stands at 10.59X, above 3.64X for its Zacks sub-industry, 4.04X for the broader Zacks sector and 8.10X for the S&P 500.
That premium does not mean the rally is finished. It does mean investors may need stronger clinical evidence before assuming the recent momentum can continue unchecked.
The valuation setup favors selectivity. For new buyers, the stock’s next leg likely depends less on enthusiasm and more on whether upcoming data confirm that vopimetostat can support a larger commercial opportunity.
Why Tango Cash Buys Time but Not Certainty
Tango ended March 31, 2026, with $379.8 million in cash, cash equivalents and marketable securities. Management expects that balance to fund operations into 2028.
That runway matters. It gives Tango time to advance several programs, absorb near-term development spending and pursue key readouts without immediate financing pressure.
Still, cash does not remove clinical risk. Larger late-stage studies could raise spending needs, especially if timelines extend or data force Tango to adjust its development strategy.
How TNGX Ranking Signals Shape the Debate
The bottom line is that TNGX still offers meaningful clinical upside, but the easy part of the trade may have passed. The stock’s premium valuation, lack of product revenue and dependence on upcoming data make the risk-reward profile more balanced after the rally.
TNGX currently carries a Zacks Rank #3 (Hold), along with a Value Score of F, Growth Score of F, Momentum Score of B and VGM Score of F. The Rank points to a neutral near-term earnings estimate backdrop, while the Style Scores suggest strong price momentum but weak value and growth characteristics. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
For investors, those signals are best used as entry-point tools rather than final verdicts. In Tango’s case, the stock remains event-driven, and upcoming clinical updates are likely to matter more than any single ranking metric.